Tuesday, August 18, 2026

A novel candidate #vaccine virus derived from #Japan's first #mammalian case of clade 2.3.4.4b #H5N1 highly pathogenic avian #influenza virus

 


Abstract

The development of candidate vaccine viruses (CVVs) for pre-pandemic preparedness requires attenuation of pathogenicity while maintaining immunogenicity. In this study, we developed and characterized NIID-002, a reassortant virus derived from A/Ezo red fox/Hokkaido/1/2022 (H5N1; clade 2.3.4.4b), to evaluate its suitability as a candidate vaccine. NIID-002 exhibited markedly reduced pathogenicity compared with its parental strain, while retaining broad antigenic reactivity and protein yield comparable to other clade 2.3.4.4b CVVs. In mammalian models, NIID-002 demonstrated strong attenuation, causing no lethal infection in mice and only minimal weight loss with limited viral replication in ferrets. Antisera raised against NIID-002 reacted broadly with recent wild-type H5N1 isolates, suggesting potential broad protection. Protein yield analysis confirmed a production efficiency comparable to that of other CVVs within the same clade, supporting its feasibility for large-scale vaccine manufacturing. Overall, NIID-002 fulfills the key requirements for the pandemic preparedness of CVV, combining reduced pathogenicity, broad antigenic reactivity, and adequate production efficiency. These findings highlight its potential as a candidate H5N1 vaccine and underscore the continued need for surveillance and refinement of influenza vaccine strategies to address evolving viral threats.

Source: 


Link: https://www.sciencedirect.com/science/article/abs/pii/S0264410X26008571?via%3Dihub

____

#Community #engagement strategies for preventing recurrent #Nipah virus #outbreaks in #Bangladesh and #India: adapting a framework for outbreak preparedness and response

 


Abstract

The Nipah virus (NiV) infection is a highly fatal zoonotic disease with pandemic potential which has led to recurrent outbreaks in Bangladesh and India. While transmission pathways, including contaminated date palm sap and human-to-human spread, are increasingly identified, significant uncertainties remain. With no approved therapeutics or vaccines, prevention depends on addressing ecological and behavioural drivers of transmission. This viewpoint draws on selected evidence from NiV outbreaks and response to other zoonotic disease epidemics, such as Ebola, rabies, and the Marburg virus disease, we seek to foster discussion on why community engagement could be central to NiV prevention and preparedness. We highlight the relevance of community engagement through a spectrum of its intensity, which distinguishes between community-oriented, community-based, community-managed, and community-owned approaches. Adapting an existing model, we discuss how community engagement principles can be applied to tackle recurring NiV outbreaks in Bangladesh and India. By aligning interventions with sociocultural realities, community engagement can improve acceptability, enhance early detection, strengthen outbreak response, and support preparedness for future vaccine and therapeutic research. However, evidence specific to NiV remains limited and lessons from other diseases should be applied judiciously. In the absence of medical countermeasures, participatory, locally grounded approaches offer a sustainable pathway to reduce recurrent outbreaks and prevent future spillover events.

Source: 


Link: https://jogh.org/2026/jogh-16-03024

____

Enhanced #Pathogenicity and Contact #Transmissibility of #Human-origin Avian #Influenza #H5N1 Clade 2.3.4.4b Genotype B3.13 Compared to D1.1 in #Ferrets

 


Abstract

Since its emergence in 2020, multiple genotypes of the H5N1 clade 2.3.4.4b have been identified, with B3.13 and D1.1 emerging in the USA as two major and concerning genotypes. However, their relative pathogenicity and transmissibility in mammals have not been fully elucidated. We compared the pathogenicity and transmissibility of the first two human H5N1 clade 2.3.4.4b cases caused by B3.13 in Texas (A/Texas/37/2024; HPhTX B3.13) and D1.1 in Louisiana (A/Louisiana/12/2024; HPhLA D1.1) in a ferret model of infection and transmission. HPhTX B3.13 infection resulted in more severe clinical disease and enhanced viral shedding, with evidence of increased transmission relative to HPhLA D1.1. Histopathological analysis revealed more extensive lung pathology in animals infected with HPhTX B3.13, consistent with increased viral loads and inflammatory responses. Importantly, both genotypes showed no significant differences in reactivity to ferret sera raised against candidate vaccine virus (CVV) strains, receptor binding properties, or neuraminidase (NA) activity and thermostability. Whole-genome sequencing revealed no adaptive mutations in HPhTX B3.13 following infection or transmission. In contrast, HPhLA D1.1 showed rapid acquisition of the mammalian-adaptive mutation E627K in infected ferrets and both E627K and Q194K in the only fatal contact animal. Both mutations were associated with enhanced polymerase activity and computational analyses suggested that they enhance interactions with the mammalian host factors ANP32A and B. Our findings indicate that B3.13 is already well adapted for mammalian infection and transmission whereas D1.1 retains evolutionary potential through the rapid acquisition of adaptive mutations, highlighting important genotype-specific differences relevant to zoonotic risk assessment and pandemic preparedness.


Competing Interest Statement

The A.G.-S. laboratory has received research support from Avimex, Dynavax, Pharmamar, and Accurius, outside of the reported work within the last three years. A.G.-S. has consulting agreements for the following companies involving cash and/or stock within the last three years: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, Avimex, Pagoda, Accurius, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Virofend, Prosetta and A.A.C.T., outside of the reported work. A.G.-S. has been an invited speaker in meeting events within the last three years organized by Seqirus, Novavax and Hipra. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work. The Icahn School of Medicine at Mount Sinai has licensed some of these inventions to Medimmune, Avimex, Leinco Technologies, Castlevax, Virofend, Kerafast, Cell Signaling, EMD Millipore, Genentech, Paratus and Nura Bio, and as a result receives financial compensation. Subject to Mount Sinai receiving such financial consideration, AG-S will receive a portion of that consideration pursuant to the terms of the Mount Sinai Intellectual Property Policy. All other authors declare no commercial or financial conflict of interest.


Funder Information Declared

NIH/NIAID, 75N93021C00014

Horizon Europe Program, KAPPA-FLU no. 101084171

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.08.10.744032v1

____

#USA, Public health officials report first #Idaho #WNV #encephalitis case of 2026 (DoH, August 18 '26)

 


    Idaho’s first reported case of human West Nile virus (WNV) meningitis this year was identified in a Canyon County resident over the age of 65. This person had been hospitalized for the illness but is recovering at home. 

    WNV is spread by the bite of an infected mosquito and can lead to severe disease in some people. West Nile neuroinvasive disease is a rare but serious complication of West Nile virus infection that occurs when the virus affects the brain or spinal cord, causing conditions such as meningitis, encephalitis (swelling of the brain), or paralysis.

    “If you or someone you know takes medications that suppress your immune system, such as treatments for cancer, autoimmune diseases, or organ transplants, your risk of developing severe West Nile virus illness after a mosquito bite, including death may be up to 40% higher,” said Southwest District Health Epidemiologist Lekshmi Rita Venugopal. 

    “With West Nile virus detected in mosquitoes in Southwest Idaho again this summer, it's especially important for people with weakened immune systems to avoid mosquito bites.”

    Idaho State Epidemiologist Dr. Christine Hahn said public health officials strongly encourage Idahoans to protect themselves and their families from mosquito bites.

    “The report of the first severe West Nile virus disease of the season in an Idaho resident is a good reminder for all of us to take protective measures against mosquito bites,” she said. 

    “This includes wearing insect repellent and protective clothing in addition to reducing standing water around gardens and homes where mosquitoes can lay eggs.”

    Symptoms of WNV infection often include fever, headache, body aches, nausea, and sometimes swollen lymph glands or a skin rash. 

    WNV infection can result in severe illness, especially in people 50 years or older, leading to hospitalization and even death. Talk to your healthcare provider about testing for WNV to confirm your illness.

    There are no licensed vaccines or medicines to prevent WNV disease in people. 

    To protect against WNV infection, people should avoid mosquitoes, particularly between dusk and dawn when the mosquitoes that spread WNV are most active. 

    In addition, everyone should:

        § Wear long, loose-fitting shirts and pants when outdoors and apply DEET or other EPA-approved insect repellent to exposed skin and clothing. Carefully follow instructions on the product label, especially for children.

        § Keep mosquitoes outside the home by using screens on windows and doors or air conditioning, if available. Repair or replace damaged screens. 

        § Reduce standing water on property. Check and drain toys, flowerpots, buckets, kiddie pools, and other items left outdoors that can hold water.

        § Change bird baths, static decorative ponds, kiddie pools, and animal water tanks weekly to reduce suitable mosquito habitats.

        § Consider larvicides for bodies of water that will not be used for drinking and cannot be covered or dumped out.

    WNV activity in mosquitoes has been detected in seven Idaho counties this year by participating mosquito abatement districts.

    For more information, visit the following resources:

        ° https://westnile.idaho.gov

        ° www.cdc.gov/west-nile-virus/index.html

        ° www.epa.gov/insect-repellents

        ° www.cdc.gov/mosquitoes/mosquito-control/mosquito-control-at-home.html

        ° www.cdc.gov/han/php/notices/han00532.html

(...)

Source: 


____

#Taiwan, Ministry of Health urges #Schools to prepare for start of lessons as #COVID19 #epidemic still active (August 18 '26, extract): PQ.16.1.1 Variant Predominates

 


{Excerpt}

(...)

    According to CDC monitoring data, the COVID-19 epidemic in Taiwan continues to rise

    In the 32nd week (August 9-15), there were 26,214 outpatient and emergency room visits related to COVID-19, an increase of 4.5% compared to the previous week (August 2-8). 

    Last week (August 11-17), there were 84 new locally transmitted severe cases and 12 new locally transmitted deaths

    Since October 2025, there have been a total of 421 local cases of COVID-19 complicated by severe illness, of which 54 have died

    The majority of severe cases are among those aged 65 and above (73.9%) and those with a history of chronic diseases (83.6%). 88.8% of these cases have not been vaccinated this season. 

    In the past four weeks, the predominant variant strain in local cases is PQ.16.1.1. 

    The global positivity rate is trending upward, particularly in Europe and Africa, while the Western Pacific region remains at a plateau. 

    The US is experiencing a rise in cases, Japan is fluctuating around a relative high point, South Korea's situation is stable, China reached its peak and is now declining weekly, and Hong Kong's situation continues to decline

    The most prevalent global variant strain recently is PQ.16.1.1, followed by NB.1.8.1 and XFG.

(...)

Source: 


____

Monday, August 17, 2026

#Lassa fever and Argentine hemorrhagic fever #treatment in guinea pigs using broad-spectrum cap-dependent #endonuclease #inhibitors

 


ABSTRACT

The class Bunyaviricetes encompasses several highly pathogenic viruses that cause lethal hemorrhagic fevers. Due to their limited prevention and treatment options and high pathogenicity, these viruses require handling in biosafety level-4 facilities. Within the bunyaviruses, arenaviruses are particularly notable for their pathogenicity and ability to cause severe hemorrhagic disease in humans. The cap-dependent endonuclease (CEN) is a unique and crucial enzyme involved in the replication cycle of these viruses. As humans do not possess a similar enzyme, CEN represents an ideal target for antiviral drug development with reduced risk of side effects. Recently, we identified a promising CEN inhibitor (CENi) demonstrating potent inhibition of virus replication. In this manuscript, we demonstrate the successful therapeutic efficacy of CENis against Lassa fever and Argentine hemorrhagic fever virus infections in guinea pig models of lethal hemorrhagic fever. In addition, we identified several CENis with antiviral activity against other highly pathogenic arenaviruses. These findings further support the potential of CENis as therapeutic agents for arenavirus infections that cause severe and often lethal hemorrhagic fever. Collectively, our results suggest that CENis are promising candidates for pan-arenavirus therapy and may also have broader utility against other CEN-containing viruses for which no approved antiviral treatments currently exist.

Source: 


Link: https://journals.asm.org/doi/10.1128/mbio.00880-26

____

#Netherlands, #WNV detected in a #blood #donor (RIVM, August 17 '26): First case since 2020

 


    A West Nile virus infection has been confirmed in a blood donor in the Netherlands

    This occurred in August 2026 during a Sanquin study among blood donors from areas where the West Nile virus had previously been detected in humans, horses, birds or mosquitoes. 

    A laboratory test (PCR) detected the virus in the donor, who had no symptoms and is still not showing any. 

    The person lives in the province of Utrecht and has not been abroad recently. It is therefore likely that the infection was contracted in the Netherlands.


First confirmed case of infection in a human in 2026

    This is the first confirmed case of a human infection in 2026 that originated in the Netherlands. The last time people contracted a West Nile virus infection in the Netherlands was in 2020.


West Nile virus and West Nile fever

    The West Nile virus occurs in birds

    The common house mosquito can contract the virus when feeding on the blood of an infected bird. 

    An infected mosquito can then pass the virus on to other birds, to mammals such as horses, and to humans. 

    Humans and horses can fall ill with the West Nile virus, but they cannot pass the virus on to others. 

    The disease caused by the West Nile virus is called West Nile fever. 

    80 per cent of people with West Nile fever have no symptoms, 19 per cent have flu-like symptoms and 1 per cent may develop neurological symptoms

    People over 50 and people with weakened immune systems due to illness or medication have a higher risk of becoming very ill from West Nile fever. 

    A small proportion of people who have a severe form of West Nile fever may die.


Mosquitoes capable of transmitting West Nile virus are active

    The fact that, within a short space of time, a horse, a bird and a human have now tested positive for the West Nile virus in different parts of the Netherlands shows that there are mosquitoes active in the Netherlands that carry the West Nile virus. It is still very unlikely for people in the Netherlands to contract West Nile fever.


What can you do to prevent West Nile virus?

    Mosquitoes are mainly active at dusk. To minimise the risk of being bitten, you could, for example:

        § wear clothing that covers the skin (long sleeves, long trousers)

        § keep mosquitoes out (insect screens for windows/doors)

        § use mosquito repellents on exposed skin

        § sleep under a mosquito net


Cooperation and monitoring

    Experts from organisations including the National Institute for Public Health and the Environment (RIVM), the GGDs, Erasmus MC, Royal GD, WBVR, UU, Sanquin and the NVWA are monitoring the situation closely.

Source: 


Link: https://www.rivm.nl/en/news/west-nile-virus-detected-in-a-blood-donor

____

Sunday, August 16, 2026

#Coronavirus Disease Research #References (AMEDEO, August 16 '26)

 


    BMJ

  1. LANG K
    What do we know about covid-19 and smell loss?
    BMJ. 2026;394:e100155.
    PubMed        


    Int J Infect Dis

  2. SEO G, Joo H, Song K, Kim M, et al
    Corrigendum to "Static and dynamic scoring systems for post-acute sequelae of SARS-CoV-2 in a Korean Cohort" [International Journal of Infectious Diseases Volume 164, 108378, March 2026].
    Int J Infect Dis. 2026;171:108980.
    PubMed        


    Intensive Care Med

  3. DAOUD T, Villar J, Annane D
    Corticosteroids in ARDS: old controversies, new insights, and future directions.
    Intensive Care Med. 2026 Aug 13. doi: 10.1007/s00134-026-08567.
    PubMed         Abstract available


    J Infect

  4. ZHOU S, Liu C, Liu W, Cai K, et al
    Cross-Neutralizing Antibody Responses to Diverse Coronaviruses in the Human Population.
    J Infect. 2026 Aug 11:106827. doi: 10.1016/j.jinf.2026.106827.
    PubMed         Abstract available


    J Med Virol

  5. VIZGIRDA G, Underwood AP, Fahnoe U, Solund C, et al
    SARS-CoV-2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History.
    J Med Virol. 2026;98:e71054.
    PubMed         Abstract available


    Lancet

  6. SCHWARTZ CA, Weiss Y
    Hate has no place in medicine.
    Lancet. 2026;408:606.
    PubMed        


    Lancet Infect Dis

  7. HE P, Song Y, Guo C, Yu L, et al
    Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1.
    Lancet Infect Dis. 2026 Aug 13:S1473-3099(26)00429.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 16 '26)-

 


    Biochem Biophys Res Commun

  1. RAO RM, Kumar N, P SP, Rao MJ, et al
    Convergent genetic and structural parameters of cardiovascular disease related insights of post-acute COVID-19.
    Biochem Biophys Res Commun. 2026;831:154319.
    PubMed         Abstract available

  2. LIU C, Yan Z, Tao Z, Yang W, et al
    C5a-C5aR1 axis activation drives neutrophil extracellular trap formation in SARS-CoV-2 N protein-mediated acute kidney injury.
    Biochem Biophys Res Commun. 2026;831:154305.
    PubMed         Abstract available


    J Clin Microbiol

  3. AEBISCHER A, Gunther A, Piesche R, Wernike K, et al
    Development of a multi-species luciferase-based double-antigen ELISA for the detection of antibodies against influenza A virus H5 clade 2.3.4.4b.
    J Clin Microbiol. 2026 Aug 13:e0190725. doi: 10.1128/jcm.01907.
    PubMed         Abstract available


    J Gen Virol

  4. LOZANO-MONTALBA L, Denis Z, Courgnaud V, Moreno-Garcia J, et al
    Glycosphingolipids are essential entry factors for non-influenza orthomyxoviruses.
    J Gen Virol. 2026;107.
    PubMed         Abstract available


    J Immunol

  5. MCKERNAN KE, Cephus JY, Kuehnle SN, Henriquez-Pilier E, et al
    Deficiency in circulating T cells in four core genotypes mice with Sry translocation.
    J Immunol. 2026;215:vkag207.
    PubMed         Abstract available


    J Infect

  6. HANSEN CL, Shaikh N, Naeger S, Torcel-Pagnon L, et al
    Hospitalizations and deaths from major respiratory viruses in the US: An ensemble time series modeling study, 2016-2025.
    J Infect. 2026;93:106811.
    PubMed         Abstract available

  7. VINK E, Murphy ME, Gunson R, MacConnachie A, et al
    Respiratory viral detection in adult severe acute respiratory infection post-COVID-19 pandemic: implications for antimicrobial stewardship.
    J Infect. 2026;93:106805.
    PubMed         Abstract available

  8. RAN J, Zhu L, Ning M, Zhang W, et al
    Age-associated impairment of humoral and cellular immune responses to SARS-CoV-2 in a large community cohort with hybrid immunity.
    J Infect. 2026 Jul 1:106803. doi: 10.1016/j.jinf.2026.106803.
    PubMed         Abstract available

  9. KONG M, Gao HX, Song XD, Yang GJ, et al
    Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5/BF.7 breakthrough infection.
    J Infect. 2026 Jun 18:106799. doi: 10.1016/j.jinf.2026.106799.
    PubMed         Abstract available

  10. ATUKORALE VN, Kwong JC, Hernandez A, Moineddin R, et al
    Factors associated with severe health outcomes among community-dwelling older adults hospitalized with respiratory syncytial virus.
    J Infect. 2026;93:106797.
    PubMed         Abstract available

  11. DONG S, Li M, Huo D, Zhao H, et al
    Impact of EV-A71 vaccination and non-pharmaceutical interventions on hand, foot, and mouth disease: A 14-year interrupted time series analysis.
    J Infect. 2026;93:106795.
    PubMed         Abstract available

  12. TRUONG T, Radin JM, Li L, Ordonez-Mena JM, et al
    Burden and economic impact of RSV hospitalisations among English adults, 2023/24.
    J Infect. 2026;93:106792.
    PubMed         Abstract available

  13. WANG X, Yin J, Xu B, Guanhua X, et al
    Clinical epidemiological characteristics of hospitalized pediatric Mycoplasma pneumoniae pneumonia in China.
    J Infect. 2026 Jun 10:106793. doi: 10.1016/j.jinf.2026.106793.
    PubMed         Abstract available


    J Virol

  14. PULIT-PENALOZA J, Belser JA, Brock N, Kieran TJ, et al
    Risk assessment of avian influenza A(H5N5) virus from the first human case using the ferret model.
    J Virol. 2026 Aug 11:e0085626. doi: 10.1128/jvi.00856.
    PubMed         Abstract available


    N Engl J Med

  15. LIU Z, Zhang L, Jiang M
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
    N Engl J Med. 2026;395:724.
    PubMed        

  16. LOCQUET M, Dogne JM
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
    N Engl J Med. 2026;395:724-725.
    PubMed        

  17. HUANG G, Das R, Wilson E
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. Reply.
    N Engl J Med. 2026;395:725-726.
    PubMed        


    Pediatrics


  18. Recommendations for Prevention and Control of Influenza in Children, 2026-2027: Policy Statement.
    Pediatrics. 2026 Aug 10. doi: 10.1542/peds.2026-078778.
    PubMed         Abstract available


  19. Recommendations for Prevention and Control of Influenza in Children, 2026-2027: Technical Report.
    Pediatrics. 2026 Aug 10. doi: 10.1542/peds.2026-078779.
    PubMed         Abstract available


    PLoS Comput Biol

  20. FORNA A, Damodaran L, Gunning CE, Rahimi P, et al
    Alignment-free prediction of cross-reactivity in influenza A (H3N2) anticipates antigenic drift.
    PLoS Comput Biol. 2026;22:e1014628.
    PubMed         Abstract available


    PLoS One

  21. MURPHY C, Cheng SMS, Mak L, So HC, et al
    Diagnostic agreement between Rhinoswabs and joint nose and throat swabs for the detection of influenza and SARS-CoV-2 among symptomatic ambulatory patients in Hong Kong.
    PLoS One. 2026;21:e0355869.
    PubMed         Abstract available

  22. KILDAY D, Korvink M, Tatum D, Cao Z, et al
    Association between COVID-19 by variant period and delivery-related outcomes in the United States.
    PLoS One. 2026;21:e0355223.
    PubMed         Abstract available

  23. TAMAKI S, Kawashima R, Uematsu T, Kawakami F, et al
    Eosinophil-associated intestinal immune responses following SARS-CoV-2 infection in K18-hACE2 mice.
    PLoS One. 2026;21:e0355607.
    PubMed         Abstract available

  24. PIETAN L, Phillippi E, Melo M, El-Shanti H, et al
    Genome-wide machine learning analysis of anosmia and ageusia with COVID-19.
    PLoS One. 2026;21:e0355832.
    PubMed         Abstract available

  25. CHEN PY, Dang LH, Hung SH
    The association between meteorological factors and influenza incidence in Taiwan: Regional heterogeneity and subtropical climate variability.
    PLoS One. 2026;21:e0355559.
    PubMed         Abstract available

  26. PARK S, Kwon JA, Kim HS, Choi Y, et al
    Socioeconomic differences in influenza vaccination coverage by government financial support status: A population-based study in Korea.
    PLoS One. 2026;21:e0353764.
    PubMed         Abstract available

  27. ALSHAHRANI A, Reddy RS, Gular K, Kakaraparthi VN, et al
    Postural control and trunk mobility impairments in adults with long COVID: A cross-sectional study using computerized posturography and clinical biomechanical tools.
    PLoS One. 2026;21:e0354593.
    PubMed         Abstract available

  28. TUT G, Lancaster T, Sylla P, Bone D, et al
    High rates of SARS-CoV-2 reinfection in residents of long term care facilities despite robust spike-specific immunity following serial vaccination.
    PLoS One. 2026;21:e0354079.
    PubMed         Abstract available

  29. KIM Y, Lee J, Park J
    Concentration of hospital utilization in the capital area among elderly inpatients from non-capital regions in South Korea: Before and during the COVID-19 pandemic.
    PLoS One. 2026;21:e0336744.
    PubMed         Abstract available

  30. FREIRE SF, Shimizu IS, Lima CAS, Adhikari NKJ, et al
    The association between resource availability and knowledge, attitudes, and practice about protective ventilation among ICU directors - A nationwide cross-sectional survey.
    PLoS One. 2026;21:e0355354.
    PubMed         Abstract available

  31. KARADUMAN E, Toprak N, Cevik A, Erail S, et al
    Factors associated with fear and coping strategies during pandemic in female university students: The moderator role of physical activity and infection status.
    PLoS One. 2026;21:e0355544.
    PubMed         Abstract available

  32. IRIEMENAM NC, Osawe S, Akanbi OA, Akinmulero O, et al
    High prevalence of SARS-CoV-2 antibodies among frontline healthcare workers during the COVID-19 pandemic in three states of Nigeria from August to December 2022.
    PLoS One. 2026;21:e0354606.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  33. DIAZ TOVAR JS, Dos Reis FP, Moriyama LT, Pego-Fernandes PM, et al
    Anatomy-resolved digital twin framework for personalized light dosimetry in lung therapies.
    Proc Natl Acad Sci U S A. 2026;123:e2612370123.
    PubMed         Abstract available


    Vaccine

  34. GEBREMARIAM AG, Genie M, Le H, Regan A, et al
    Vaccine uptake in the context of mandate announcement and removal: Evidence from Europe and North America.
    Vaccine. 2026;88:128825.
    PubMed         Abstract available

  35. FAVRE G, Pfund A, Gerbier E, Anselem O, et al
    Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings.
    Vaccine. 2026;88:128783.
    PubMed         Abstract available

  36. CARAZO S, Skowronski DM, Sauvageau C, Talbot D, et al
    2024/25 end-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada.
    Vaccine. 2026;88:128786.
    PubMed         Abstract available

  37. EBRAHIMI N, de Whalley P, Kanji N, Ramasamy MN, et al
    ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.
    Vaccine. 2026;88:128951.
    PubMed         Abstract available

  38. DALEXIS RD, Beogo I, Xu Y, Muray M, et al
    Post-COVID-19 pandemic inequities in routine childhood immunization in Canada: racial disparities in uptake of polio, meningococcal conjugate, and varicella vaccines.
    Vaccine. 2026;88:128931.
    PubMed         Abstract available

  39. HUSSAIN HS, Yousafzai MT, Iqbal J, Aslam ZM, et al
    Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan.
    Vaccine. 2026;88:128918.
    PubMed         Abstract available

  40. YOON SK, Phillips AL, Battan-Wraith S, Thiese MS, et al
    Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial).
    Vaccine. 2026;88:128954.
    PubMed         Abstract available

  41. DIARRA M, Li S, Gaur S, Greenberg P, et al
    Understanding parent motivation for participating in the Pfizer COVID-19 vaccine trial.
    Vaccine. 2026;88:128960.
    PubMed         Abstract available

  42. BELL S, Chantler T, Passanante A, Pryce J, et al
    Maternal respiratory syncytial virus (RSV) vaccine perceptions amongst pregnant women and mothers of infants and toddlers in England: a qualitative study.
    Vaccine. 2026;88:128955.
    PubMed         Abstract available

  43. MAEDA H, Igarashi A, Mitsui S, Suzuki K, et al
    Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged >/=60 years, Japan, October 2024-April 2025.
    Vaccine. 2026;88:128964.
    PubMed         Abstract available

  44. BARASA L, Onyango G
    The institutional roots of vaccine uptake and hesitancy: evidence from Africa.
    Vaccine. 2026;88:128980.
    PubMed         Abstract available

  45. LI J, Wang Z, Gong Y
    Country-level immunization recovery and DTP1 no-dose proxy burden after COVID-19: a descriptive ecological analysis of WUENIC, 2010-2024.
    Vaccine. 2026;88:128973.
    PubMed         Abstract available

  46. KIM T, Wang X, Rajtmajer S, Harden JJ, et al
    Elected officials' online anti-vaccination statements respond to online engagement.
    Vaccine. 2026;88:128901.
    PubMed         Abstract available

  47. C M, Dymock M, Flanagan KL, Plebanski M, et al
    The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults.
    Vaccine. 2026;88:128970.
    PubMed         Abstract available

  48. DE PADUA MC, Antunes MOB, Stein RT, Pinto LA, et al
    Effectiveness of BNT162B2 and CoronaVac vaccines in reducing COVID-19 severity among children aged 3-4 years in Brazil.
    Vaccine. 2026;88:128974.
    PubMed         Abstract available

  49. TAY CJX, Koh CWT, Ooi JSG, Li HE, et al
    Over-induction of innate immune responses suppresses T cell response to mRNA SARS-CoV-2 vaccination.
    Vaccine. 2026;88:128983.
    PubMed         Abstract available

  50. RAFIZADEH A, Wijekoon D, Aung ET, Aguirre I, et al
    Influenza vaccination uptake among people living with HIV in Melbourne, 2015-2025: a repeated cross-sectional study.
    Vaccine. 2026;90:129038.
    PubMed         Abstract available

  51. SAITOH A, Takaku M
    Partner awareness and support for maternal RSV vaccination: a paired survey of pregnant women and co-residing partners in Japan.
    Vaccine. 2026;88:128946.
    PubMed         Abstract available

  52. PAUL KK, Newall AT
    The cost of respiratory syncytial virus (RSV) across all ages to the Australian healthcare system.
    Vaccine. 2026;88:128922.
    PubMed         Abstract available

  53. AUNG TN, Muyindike W, Hoeppner SS, Nanfuka V, et al
    COVID-19 vaccination among people with HIV in Uganda: lessons from a high-risk group with high vaccine uptake for the next pandemic.
    Vaccine. 2026;88:128912.
    PubMed         Abstract available

  54. HENSLEY AA, Jiles KA, Edwards S, Clinchard C, et al
    Characteristics of successful and unsuccessful strategies to increase vaccine intention and improve vaccine uptake for U.S. adult populations in the Affordable Care Act era (2010-2025): a systematic review and meta-regression.
    Vaccine. 2026;88:128910.
    PubMed         Abstract available

  55. MCCONEGHY KW, Wilker EH, DeVone F, Skov B, et al
    Vaccine effectiveness of mRNA-1345 against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans, 2025-2026.
    Vaccine. 2026;88:128882.
    PubMed         Abstract available

  56. NAKANO T, Iwata S, Oishi K, Iguchi E, et al
    Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.
    Vaccine. 2026;88:128871.
    PubMed         Abstract available

  57. MALTEZOU HC, Borg M, Botelho-Nevers E, Brantsaeter AB, et al
    Vaccination policies for healthcare personnel in Europe, 2026.
    Vaccine. 2026;88:128839.
    PubMed         Abstract available

  58. MYERS TR, Zauche LH, Marquez PL, McCullum I, et al
    V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.
    Vaccine. 2026;88:128725.
    PubMed         Abstract available

  59. PRAT-AYMERICH C, Yeghiazaryan L, Pathirana RD, Gautier V, et al
    A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc tri
    Vaccine. 2026;88:128769.
    PubMed         Abstract available

  60. SINGER D, La EM, Dubois de Gennes C, Graham J, et al
    Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.
    Vaccine. 2026;88:128770.
    PubMed         Abstract available

  61. GONDWE KW, Hearst MO, Mbutuka HR, Khwepeya M, et al
    Factors associated with COVID-19 vaccine acceptance among refugee women at Dzaleka refugee camp in Malawi.
    Vaccine. 2026;88:128862.
    PubMed         Abstract available

  62. LIU Z, Wang X, Hu Y, Duan X, et al
    Burden of infection and hospitalization from respiratory syncytial virus-associated acute lower respiratory tract infections in Chinese children: Modeling of national, regional, and provincial estimates.
    Vaccine. 2026;88:128875.
    PubMed         Abstract available

  63. MORIO R, Takazono T, Morimoto S, Ashizawa N, et al
    Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study.
    Vaccine. 2026;88:128861.
    PubMed         Abstract available

  64. TORKAMAN-ASADI F, Bakhtiari S, Safarzadeh M, Riahi-Rad Z, et al
    Clinical outcomes among SARS-CoV-2 omicron-infected adults according to prior infection and vaccination history in Iran: A retrospective registry-based study.
    Vaccine. 2026;88:128868.
    PubMed         Abstract available

  65. FLEMING JA, Colistro V, Knudson S, Colomar M, et al
    Timing and frequency of antenatal care visits in relation to maternal respiratory syncytial virus vaccine opportunities in four Latin American countries.
    Vaccine. 2026;88:128854.
    PubMed         Abstract available

  66. ASAGA PM, Kroeger A, Yako A, Makpo J, et al
    Global misinformation, local consequences: conspiracy theory endorsement and a graded association with COVID-19 vaccine refusal across Nigeria.
    Vaccine. 2026;88:128827.
    PubMed         Abstract available

  67. RICKE IJ, Ward C, Spaulding AB, Sherwood NE, et al
    Caregiver COVID-19 vaccine status and its influence on pediatric vaccination decisions in a US cohort.
    Vaccine. 2026;88:128847.
    PubMed         Abstract available

  68. RAZZAGHI H, Garacci E, Kahn KE, Meghani M, et al
    Maternal and infant immunizations for respiratory diseases, United States, may 2025.
    Vaccine. 2026;88:128823.
    PubMed         Abstract available


    Virology

  69. BYRNE AMP, James J, Thomas SS, Warren CJ, et al
    Impact of prior low-pathogenicity avian influenza H7N7 exposure on susceptibility and protection against homologous high-pathogenicity avian influenza H7N7 challenge in chickens.
    Virology. 2026;624:111047.
    PubMed         Abstract available

History of Mass Transportation: The Diesel Hydraulic Multiple Unit MAN/Linke-Hoffman Busch of Poland Railways


 {Click on Image to Enlarge}

__

By Grzegorz W. Tężycki - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=65730961

Source: 


Link: https://en.wikipedia.org/wiki/List_of_rolling_stock_used_in_Poland

____

The Tower of Babel, Pieter Bruegel the Elder (1563)

 


{Click on Image to Enlarge}

__

Public Domain.

Source: 


Link: https://www.wikiart.org/en/pieter-bruegel-the-elder/the-tower-of-babel-1563

____

Saturday, August 15, 2026

The association of empirical #treatment with #oseltamivir with the #outcome of critically ill patients admitted with severe acute respiratory illness (#SARI)

 


Abstract

Objective

Neuraminidase inhibitors (NAIs) are widely used empirically in critically ill patients with suspected influenza; however, their effect on mortality remains uncertain. This multicenter study evaluates the association between empirical treatment with oseltamivir and the outcome of critically ill patients with Severe Acute Respiratory Infection (SARI) admitted to the Intensive Care Unit (ICU).

Methods

This was a retrospective cohort study conducted in the ICUs of four hospitals in Saudi Arabia, involving adult patients with SARI from September 2012 to December 2018. Data collected were: demographics, comorbidities, clinical presentation, and outcomes among patients treated with oseltamivir and those who were not. The primary outcome was 90-day mortality. The association of oseltamivir and mortality was evaluated adjusting for propensity score.

Results

During the study period, 456 patients with SARI were included in the study, 301 were treated with empirical oseltamivir within a median of 1 day from presentation (interquartile range, 0-1 day) and a median of 4 days after symptom onset, while 155 patients were not. No significant differences were observed in baseline characteristics between the two groups. Of the included patients, 334 (73%) were tested for influenza using PCR, and 87 (26%) had a confirmed diagnosis of influenza. Patients on oseltamivir were less likely to require rescue oxygen therapy (22.9% vs. 34.8%, p=0.007), and had shorter hospital stay (20 days vs. 27 days, p=0.01). Patients treated with oseltamivir had significantly reduced 90-day mortality on adjusted analyses (aOR: 0.87, 95% CI: 0.81-0.94, p=0.0002). Subgroup analysis revealed that the association with reduced mortality extends to patients >70 years old (aOR: 0.94, 95% CI: 0.89-0.99, p=0.02) and those with negative influenza tests (aOR: 0.81, 95% CI: 0.79, 0.84, p<0.0001).

Conclusion

Among critically ill patients with SARI, empirical treatment with oseltamivir was associated with lower mortality. These results add to the body of evidence suggesting clinical benefits of oseltamivir in managing critically ill patients with influenza-like illnesses.

Source: 


Link: https://journals.sagepub.com/doi/10.1177/20503121261478401

____

High rates of #SARS-CoV-2 #reinfection in residents of long term care facilities despite robust #spike-specific #immunity following serial #vaccination

 


Abstract

Older adult residents of long-term care facilities (LTCFs) suffered high rates of mortality during the initial stages of the COVID-19 pandemic but their clinical risk has decreased markedly following vaccination. Here we determined humoral and cellular immunity following delivery of a 5th vaccine dose, an mRNA spike B1:BA.1 bivalent vaccine, to care home residents. The delivery of a 5th vaccine elicited a plateau of spike-specific immunity that remained broadly stable over 100 days in almost all people. Despite this, 15% of residents had a primary infection and 30% became reinfected during 6-months of follow up. These findings reveal that serial vaccine delivery can establish robust systemic spike-specific immune responses in frail older people but that this does not reliably prevent SARS-CoV-2 reinfection. As such, additional approaches should be considered to reduce reinfection risk in this vulnerable population group.

Source: 


Link: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0354079

____

History of Mass Transportation: The DRB Class 03 Steam Locomotive of Poland Railways

 


{Click on Image to Enlarge}

___

By The original uploader was Wassen at German Wikipedia.(Original text: wassen) - Self-photographed, CC BY-SA 2.0 de, https://commons.wikimedia.org/w/index.php?curid=3737550

Source: 


Link: https://en.wikipedia.org/wiki/List_of_rolling_stock_used_in_Poland#/media/File:Pm_3-5_als_Pm_3-3_Warszawa_06.04.05.jpg

____

#Ebola disease caused by #Bundibugyo virus - #DRC (WHO D.O.N., August 15 '26): 4,665 cases and 2,184 deaths so far

 


Situation at a glance

    The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo is in a phase of intense transmission

    It is the largest Ebola outbreak ever reported in the country and expanding faster than any previous Ebola outbreak. 

    The epidemic is increasingly characterized by sustained transmission within interconnected geographic clusters. 

    Initially confined to the Mongbwalu health zone in Ituri Province, the outbreak has now expanded to 54 health zones across six provinces (Ituri, North Kivu, South Kivu, Haut-UĂ©lĂ©, Tshopo, and Bas-UĂ©lĂ©). 

    The most recently affected Bas-UĂ©lĂ© province recorded one confirmed case in Buta health zone with travel history to Haut-UĂ©lĂ© and onset of symptoms on 4 August. 

    As of 12 August 2026, a total of 4665 confirmed cases, including 2184 deaths, have been reported, corresponding to a crude case fatality ratio (CFR) of 46.8%. 

    The ongoing rise in cases, broader geographic spread, and continued high mortality demonstrate the rapidly changing scope of this public health emergency of international concern

    During the most recent reporting week (epidemiological week 32, 3 to 9 August 2026), the highest weekly number of reported cases (579) and deaths (304) were recorded, highlighting the exceptional pace of transmission

    The ongoing humanitarian crisis, compounded by insecurity, population displacement and mobility, and cross-border movements, continues to pose significant challenges to response efforts and increase the risk of further geographical spread. 

    National authorities in the Democratic Republic of the Congo, continue to implement extensive response measures in collaboration with WHO and partners. 

    However, a substantial scaling up of response activities is underway to get ahead of the outbreak. 

    Following their missions to the Democratic Republic of the Congo, WHO’s Director-General and Regional Director for Africa, and the Director General of Africa CDC, highlighted surveillance activities and closer work with communities as priority areas. 

    Expanding the number of treatment centers, across more areas, is underway, along with training for the health and care workers to staff them. 

    France has reported no secondary transmission following an imported case detected on 24 June 2026. 

    As of 14 August, 41 days had passed since the patient’s discharge on 4 July, with no additional confirmed cases reported. 

    In Uganda the most recent imported case was discharged from a treatment centre on 16 July, and the 42-day enhanced monitoring period will cease on 27 August

    Uganda remains at risk of BVD re-introduction due to ongoing transmission in neighbouring Democratic Republic of the Congo and is undertaking heightened surveillance activities given continued population movement and the risk of cross-border transmission. 

    A regional preparedness and prioritization framework continues to guide readiness and response activities across the African Region.


Description of the situation

    Since the previous Disease Outbreak News was published on 1 August 2026, additional confirmed cases and deaths of BVD have been only reported in the Democratic Republic of the Congo.  

    Cumulatively as of 12 August 2026, 4686 confirmed cases have been reported: 4665 in the Democratic Republic of the Congo (including two cases diagnosed in the Democratic Republic of the Congo and subsequently treated in Germany), 20 in Uganda and one in France

    A total of 2186 deaths have been reported, including two in Uganda. 

    As of 12 August, at least 986 patients have recovered including 965 in the Democratic Republic of the Congo, 18 from Uganda have recovered, two in Germany and one from France.  

    As reported in the Disease Outbreak News published on 1 August 2026, with more confirmed cases than the 2018-2020 outbreak, which reported 3,317 cases, this outbreak now represents the largest Ebola disease outbreak ever documented in the country. 

(...)


Democratic Republic of the Congo  

    Since 1 August 2026 when the last Disease Outbreak News was published, an additional 1060 confirmed cases, including 597 confirmed deaths, have been reported in the Democratic Republic of the Congo. 

    The increase is in part due to strengthened surveillance activities, enhanced laboratory testing, and diagnostic capacity. However, most of the increase reflects the expansion of the outbreak.  

    As of 12 August 2026, a total of 4665 confirmed cases, including 2184 deaths (CFR 46.8%), have been reported in the Democratic Republic of the Congo. To date, 965 patients have recovered. 

    Cases have been reported from 54 health zones (HZ) across six provinces: Ituri (28/36 HZ), North Kivu (12/34 HZ), South Kivu (1/34 HZ), Haut-UĂ©lĂ© (6/13 HZ), Tshopo (6/23 HZ), and Bas- UĂ©lĂ© (1/11 HZ). The most recently affected province, Bas-UĂ©lĂ©, reported one confirmed case in Buta Health Zone. The case had a travel history to Haut-UĂ©lĂ©, with symptom onset on 4 August. 

    As of 12 August, of the 54 affected health zones, 100 new confirmed cases were reported in the last 24 hours from 22 health zones in all affected provinces except for Sud-Kivu. 

    The highest number of new cases in the last 24 hours (67) was reported from Ituri province followed by Nord-Kivu (25). Ituri remains the most affected province, accounting for 85% (3979/4665) of all confirmed cases and 79% (1726/2184) of reported deaths nationwide.  

    As of 12 August, the proportion of contacts followed up in the last 24 hours is at 84.2% (17 460 seen out of 20 740 to follow up). 

    As of 9 August, infections among health workers continue, with at least 155 confirmed cases, including 45 deaths (CFR: 29%) and 68 recoveries since beginning of the outbreak. These infections highlight ongoing occupational exposure risks, persistent challenges in implementing infection prevention and control (IPC) in health-care facilities—especially outside of the designated Ebola treatment centres which have more established protocols and access to supplies--and continued exposure risk in the community. 

    The outbreak is taking place amid a severe humanitarian crisis and ongoing insecurity, characterized by large-scale population displacement, significant population mobility, and constrained access to critical services, including health care, safe water, food, shelter, and protection. 

    Response efforts in the affected provinces have been hindered by insecurity and attacks on health facilities, which have curtailed access for response teams, discouraging potential patients from seeking care, disrupting surveillance and response activities and increasing the risk of undetected transmission. 

    Since the declaration of the Ebola public health emergency of international concern (PHEIC) on 17 May 2026, 12 attacks on health care have been recorded, with additional reports under verification. These challenges underscore the importance of community-centred response efforts led by local authorities and trusted community leaders.  


Figure 2: Number of confirmed cases (n = 4665), in the Democratic Republic of the Congo, by date of reporting and as of 12 August 2026 


{Click on Image to Enlarge}

___

Figure 3: Number of deaths among confirmed cases (n = 2184), in the Democratic Republic of the Congo, by date of reporting, as of 12 August 2026



{Click on Image to Enlarge}

___


{*} Note that the large number of reported deaths on 22 July represents the completion of a data reconciliation exercise, including deaths that occurred earlier in the outbreak, rather than newly recorded deaths. 


Epidemiology

    Bundibugyo virus disease (BVD) is a severe Ebola disease caused by the Bundibugyo virus, one of the Orthoebolavirus species. It is a zoonotic disease, with fruit bats suspected to be the natural reservoir. 

    Human infection is thought to occur through close contact with the blood or secretions of infected wildlife, such as bats or non-human primates, and it subsequently spreads from person-to-person through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals or contaminated surfaces and materials. Transmission is particularly amplified in health-care settings when IPC measures are inadequate and during unsafe burial practices involving direct contact with deceased individuals. 

    The incubation period for BVD ranges from two to 21 days, and infected individuals are not infectious until symptom onset. Early symptoms such as fever, fatigue, muscle pain, headache, and sore throat are non-specific, which complicates clinical diagnosis and can delay detection. These symptoms then progress to gastrointestinal symptoms, organ dysfunction, and, in some cases, haemorrhagic manifestations. 

    CFRs in the past two BVD outbreaks, reported in Uganda and in the Democratic Republic of the Congo in 2007 and 2012, were 30% and 50%, respectively. 

    Differentiating BVD from other endemic febrile illnesses such as malaria is challenging without laboratory confirmation using PCR or antigen- or antibody-based assays. Outbreak control relies on rapid case identification, isolation and care, contact tracing, safe burials and strong community engagement, as no approved vaccines or specific treatments currently exist for BVD. 


Public health response

    For detailed information about the ongoing public health response actions by the respective Ministry of Health, WHO and partners please refer to the latest situation reports published by the WHO Regional Office for Africa: Ongoing outbreak in the Democratic Republic of the Congo | WHO | Regional Office for Africa | WHO| Regional Office for Africa  

    Health authorities in the Democratic Republic of the Congo, in collaboration with WHO and partners, are continuing to implementing extensive public health measures, including: 

    ° the continental preparedness and response plan, 

    ° a strategic six-month framework plan designed to guide coordinated efforts to strengthen outbreak response measures, including 

    ° emergency coordination, 

    ° disease surveillance, 

    ° laboratory testing, 

    ° infection prevention and control, 

    ° clinical care, 

    ° community engagement, 

    ° research, 

    ° logistics and support for essential health services, 

    ° engaging donors and mobilizing additional resources to address critical funding gaps and 

    ° sustain response operations across affected and at-risk areas. 


    A substantial scale-up is ongoing across all response pillars to get ahead of the outbreak.


WHO risk assessment

    On 6 June 2026, WHO reassessed the risk of the outbreak of BVD to incorporate newly available information and align with the WHO Temporary Recommendations. 

    The risk for countries sharing land borders with countries with documented Bundibugyo virus detection, the Democratic Republic of the Congo and Uganda at the time of assessment, was separated from the risk for other countries in the African Region. 

    The risk in the Democratic Republic of the Congo was assessed as very high due to ongoing transmission and the continued expansion of the outbreak into new health zones, increasing the potential for further national and regional spread. 

    The risk in Uganda was assessed as high due to confirmed cross-border spread through imported cases and ongoing epidemiological links along the eastern Democratic Republic of the Congo–western Uganda corridor, which has historically been affected by Ebola outbreaks, including Bundibugyo virus and Sudan virus disease.  

    The risk for countries sharing land borders with countries reporting BDBV detection was assessed as high due to sustained population mobility linked to cross-border trade and mining activities, variation in capacities and experience of BVD response, and variable levels of readiness.  

    The risk for the rest of the African region and at the global level was assessed as low

    For further information, please see the WHO Rapid Risk Assessment – Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo, Uganda and countries with land borders adjoining countries with documented BDBV detection v3. 

    An updated Rapid Risk Assessment is being developed in advance of the upcoming IHR Emergency Committee meeting regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic Republic of the Congo scheduled for 18 August. This is the second meeting of the committee, following their initial meeting after the Director-General characterized the situation as a Public Health Emergency of International Concern on 17 May 2026.  

(...)

Source: 


Link: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON615

____

My New Space

Most Popular Posts